Literature DB >> 11499361

Leukocytes and endothelium interaction as rate limiting step in the inflammatory response and a key factor in the ischemia-reperfusion injury.

I Maroszyńska1, P Fiedor.   

Abstract

Leukocyte-endothelium interactions play a key role in regulation of the inflammatory response, leukocytes migration and ischaemia-reperfusion injury. These adhesive reactions controlling the circulation of leukocytes, are key parts of immune surveillance arising from extravasation of neutrophils, and migration into tissue to eliminate invading microorganism. They also play important role in the generation of ischaemic-reperfusion injury of different organs including brain. Plasma levels of soluble adhesion molecules may be a diagnostic marker of the systemic endothelial injury. It is likely that the next few years bring new therapies to control leukocyte-endothelial interaction by directly inhibiting the adhesion molecules or by modulating their expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11499361

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  10 in total

Review 1.  Cell therapy, advanced materials, and new approaches to acute kidney injury.

Authors:  Alexander S Yevzlin; H David Humes
Journal:  Hosp Pract (1995)       Date:  2009-12

Review 2.  MicroRNAs as Potential Pharmaco-targets in Ischemia-Reperfusion Injury Compounded by Diabetes.

Authors:  Hassan Dehaini; Hussein Awada; Ahmed El-Yazbi; Fouad A Zouein; Khodr Issa; Assaad A Eid; Maryam Ibrahim; Adnan Badran; Elias Baydoun; Gianfranco Pintus; Ali H Eid
Journal:  Cells       Date:  2019-02-12       Impact factor: 6.600

Review 3.  Cell-based approaches for the treatment of systemic inflammation.

Authors:  Christopher J Pino; Alexander S Yevzlin; Kyungsoo Lee; Angela J Westover; Peter L Smith; Deborah A Buffington; H David Humes
Journal:  Nephrol Dial Transplant       Date:  2012-11-09       Impact factor: 5.992

4.  Role of adhesion molecules and dendritic cells in rat hepatic/renal ischemia-reperfusion injury and anti-adhesive intervention with anti-P-selectin lectin-EGF domain monoclonal antibody.

Authors:  Tong Zhou; Gui-Zhi Sun; Ming-Jun Zhang; Jin-Lian Chen; Dong-Qing Zhang; Qing-Shen Hu; Yu-Ying Chen; Nan Chen
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

Review 5.  Renal cell therapy and beyond.

Authors:  Joon Ho Song; H David Humes
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

6.  Effect of tetramethylpyrazine on P-selectin and hepatic/renal ischemia and reperfusion injury in rats.

Authors:  Jin-Lian Chen; Tong Zhou; Wei-Xiong Chen; Jin-Shui Zhu; Ni-Wei Chen; Ming-Jun Zhang; Yun-Lin Wu
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

Review 7.  The bioartificial kidney in the treatment of acute kidney injury.

Authors:  Joon Ho Song; H David Humes
Journal:  Curr Drug Targets       Date:  2009-12       Impact factor: 3.465

8.  Modulation of syndecan-1 shedding after hemorrhagic shock and resuscitation.

Authors:  Ricky J Haywood-Watson; John B Holcomb; Ernest A Gonzalez; Zhanglong Peng; Shibani Pati; Pyong Woo Park; WeiWei Wang; Ana Maria Zaske; Tyler Menge; Rosemary A Kozar
Journal:  PLoS One       Date:  2011-08-19       Impact factor: 3.240

9.  A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury.

Authors:  James A Tumlin; Claude M Galphin; Ashita J Tolwani; Micah R Chan; Anitha Vijayan; Kevin Finkel; Balazs Szamosfalvi; Devasmita Dev; J Ricardo DaSilva; Brad C Astor; Alexander S Yevzlin; H David Humes
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

10.  In vivo investigation of gingival health and oxidative stress changes in patients undergoing orthodontic treatment with and without fluoride use.

Authors:  Prasad Chitra; Govinakovi Shivamurthy Prashantha; Arun Rao
Journal:  J Indian Soc Periodontol       Date:  2022-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.